GlassScriptPhysician profile
Regina Krel
NPI 1053608257
$181,627.69
in general payments reported to CMS, 2019-2025
36 companies · $27K in 2025
The $27K reported for 2025 was more than what 94% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $802 · 2020: $16K · 2021: $60K · 2022: $42K · 2023: $19K · 2024: $17K · 2025: $27K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $50K · Food and Beverage: $5,077 · Honoraria: $3,800 · Travel and Lodging: $2,804 · Consulting Fee: $1,525.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $49,712.50 |
| Food and Beverage | $5,077.10 |
| Honoraria | $3,800.00 |
| Travel and Lodging | $2,803.72 |
| Consulting Fee | $1,525.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $96,091.20 | 2021-2025 | |
| Allergan, INC. | $28,840.64 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $15,551.93 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13,792.31 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $8,509.92 | 2019-2024 | Ajovy, Austedo Xr |
| Pfizer INC. | $8,326.07 | 2023-2025 | |
| Lundbeck LLC | $7,074.10 | 2020-2025 | Vyepti |
| Lilly USA, LLC | $838.27 | 2019-2025 | Emgality, Reyvow, Kisunla |
| Celgene Corporation | $492.70 | 2021-2025 | Zeposia |
| Biogen, INC. | $368.23 | 2019-2023 | Vumerity, Tysabri, Avonex |
| Novartis Pharmaceuticals Corporation | $359.37 | 2019-2022 | |
| Tg Therapeutics, INC. | $232.69 | 2022-2025 | |
| Axsome Therapeutics, INC. | $166.11 | 2025 | Symbravo |
| E.R. Squibb & Sons, L.L.C. | $147.77 | 2020-2021 | |
| Sk Life Science, INC. | $147.01 | 2024 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $137.49 | 2019-2025 | |
| Amgen INC. | $89.58 | 2020-2022 | |
| Currax Pharmaceuticals LLC | $73.35 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $61.37 | 2021-2022 | |
| Genentech USA, INC. | $43.18 | 2024-2025 | Ocrevus Zunovo, Ocrevus |
| Genzyme Corporation | $32.83 | 2023 | |
| Alexion Pharmaceuticals, INC. | $32.31 | 2023-2024 | Soliris, Ultomiris |
| Philips North America LLC | $20.88 | 2024 | (Ak6) Vest Therapy |
| Merz Pharmaceuticals, LLC | $18.61 | 2024 | Xeomin |
| Supernus Pharmaceuticals, INC. | $18.09 | 2021 | |
| Neurocrine Biosciences, INC. | $17.18 | 2025 | |
| Scilex Pharmaceuticals INC. | $16.95 | 2024 | |
| Mallinckrodt Enterprises LLC | $15.98 | 2019 | |
| Mallinckrodt Hospital Products INC. | $15.88 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $15.00 | 2021 | |
| Bausch Health US, LLC | $14.99 | 2019 | |
| Collegium Pharmaceutical, INC. | $14.84 | 2022 | |
| Avanir Pharmaceuticals, INC. | $14.69 | 2019 | |
| Assertio Therapeutics, INC. | $13.91 | 2020 | |
| Zyla Life Sciences, INC. | $13.75 | 2020 | |
| Impel Pharmaceuticals LLC | $8.51 | 2024 | Trudhesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Regina Krel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.